Top Markets
Coin of the day
Verici Dx plc Verici Dx plc

Verici Dx plc

VRCI
Rank in Stocks #40975
Verici Dx plc is an immuno-diagnostics company primarily focused on the kidney... Verici Dx plc is an immuno-diagnostics company primarily focused on the kidney transplantation sector. The firm specializes in creating both predictive and diagnostic assays for patients who have undergone kidney transplants. Its development pipeline features Clarava, a pre-transplant tool designed to forecast the likelihood of early acute rejection; Tuteva, a post-transplant assessment focusing on acute cellular rejection; and Protega, an innovative liquid biopsy aiming to predict the risk of fibrosis and eventual graft failure. Established in 2020, Verici Dx plc maintains its headquarters in Penarth, United Kingdom.
Share Price
$0.00338543
Market Cap
$56.59K
Change (1 day)
-0.48%
Change (1 year)
-52.51%
Country
GB
Trade Verici Dx plc (VRCI)

Category

Revenue for Verici Dx plc (VRCI)
Revenue in Aug 2026 TTM: 0
According to Verici Dx plc latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Verici Dx plc from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
$46.34B -
US
$25.11B -
US
- -
CN
$4.55B -
US
$2.71B -
US